BPC-157 is a localized repair peptide that acts at the injection site to accelerate tendon, ligament, gut, and joint healing through direct fibroblast activation and angiogenesis
Individuals experiencing fatigue, slow recovery, weight management challenges, or signs of age-related decline may benefit
In obesity, Novos Wegovy (semaglutide injection) was approved in 2021, however uptake has been hindered by access limitations, with no Medicare coverage and limited coverage among commercial plans
In clinical documentation, discomfort at the injection site, and erythema at the injection site are listed as recognized adverse effects of semaglutide (StatPearls, Semaglutide , NBK603723, NIH)
"Different foods and combinations of foods can cause blood glucose spikes," says Nasser